Sales & Earnings
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Analysts expected at least $12m in third quarter sales, but the Alzheimer’s therapy brought in just $300,000. The company says educating doctors and procuring a coverage determination from CMS – not lower pricing – are key to growth.
Ronapreve and Actemra for COVID-19 indications padded the top-line. Roche raised its financial outlook for the year to mid-single digit growth.
The company is currently providing its COVID-19 vaccine on a not-for-profit basis but expects that will change as the pandemic phase of the crisis abates.
With the latest Delta variant wave in the rear-view mirror, vaccine and antiviral sales, and their impact on full-year guidance, are likely to remain the big swing factors in third-quarter earnings season.
COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.
Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.
The company pre-announced $136m in third quarter sales, beating analyst consensus and signaling both increased oral CGRP inhibitor market share and improved per-prescription net revenue.
The stock price performances of the top two coronavirus vaccine producers are inversely correlated to their sales and pipelines. There seems to be an expectation of declining coronavirus vaccine sales for some, but not for others.
Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.
Big pharmaceutical franchises may be recovering from the pandemic, but the extent of the untreated backlog of cancer patients from 2020 is still an important unknown driver even after second-quarter earnings season, and smaller cancer companies may still be bearing the brunt of COVID-19’s effects.
Japan's top pharma firms benefited in several cases from one-off factors in what was a generally positive fiscal first quarter, but most full-year guidance remains unchanged for now.
Key brands saw growth in the first half of 2021 despite the company’s overall revenues falling, mainly due to generic competition for Northera.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.